Cbfa2 is required for the formation of intra-aortic hematopoietic clusters

Trista North[1], Ting-Lei Gu[1], Terryl Stacy[1], Qing Wang[1], Louisa Howard[2], Michael Binder[3], Miguel Marín-Padilla[4] and Nancy A. Speck[1],*

[1]Department of Biochemistry, Dartmouth Medical School, Hanover, NH 03755, USA
[2]Ripple Electron Microscope Facility, Dartmouth College, Hanover, NH 03755, USA
[3]Department of Anatomy, Dartmouth Medical School, Hanover, NH 03755, USA
[4]Departments of Pathology and Anatomy, Dartmouth Medical School, Hanover, NH 03755, USA
*Author for corrrespondence (e-mail: Nancy.Speck@dartmouth.edu)

SUMMARY

Cbfa2 (*AML1*) encodes the DNA-binding subunit of a transcription factor in the small family of core-binding factors (CBFs). *Cbfa2* is required for the differentiation of all definitive hematopoietic cells, but not for primitive erythropoiesis. Here we show that *Cbfa2* is expressed in definitive hematopoietic progenitor cells, and in endothelial cells in sites from which these hematopoietic cells are thought to emerge. Endothelial cells expressing *Cbfa2* are in the yolk sac, the vitelline and umbilical arteries, and in the ventral aspect of the dorsal aorta in the aorta/genital ridge/mesonephros (AGM) region. Endothelial cells lining the dorsal aspect of the aorta, and elsewhere in the embryo, do not express *Cbfa2*. *Cbfa2* appears to be required for maintenance of *Cbfa2* expression in the endothelium, and for the formation of intra-aortic hematopoietic clusters from the endothelium.

Key words: CBF, AML1, hematopoietic stem cells

INTRODUCTION

Hematopoietic cells differentiate from mesoderm during embryogenesis, in close association with endothelial cells. In the mouse, the first blood cells (primitive erythrocytes) and endothelial cells differentiate from mesodermal masses in the yolk sac at about 7.5 days post coitus (dpc) (Haar and Ackerman, 1971; Moore and Metcalf, 1970). The concurrent development of both lineages led to the hypothesis, many years ago, that endothelial cells and hematopoietic cells share a common precursor called the hemangioblast (Murray, 1932; Sabin, 1920). A common origin of both lineages is further supported by recent molecular and genetic analyses. For example, several cell surface markers are common to endothelial cells and hematopoietic progenitors, including CD34, Flk-1 and TIE2 (Augustin et al., 1994; Takakura et al., 1998). In addition, cells of both lineages can be cultured from mouse embryonic stem cells from a common, transient progenitor (Choi et al., 1998; Nishikawa et al., 1998a). Mutations in several genes affect both hematopoietic and endothelial cell development. *Flk1* is required for the development of primitive and definitive hematopoietic cells and endothelial cells in the embryo, and is thought to be required at the level of the hemangioblast (Shalaby et al., 1997, 1995). Disruption of *Scl* disrupts primitive and definitive hematopoiesis, and perturbs angiogenesis in the yolk sac, but does not impair the initial formation of endothelial cells (Robb et al., 1995; Shivdasani et al., 1995; Visvader et al., 1998). The *cloche* gene is also required for normal blood and endothelial cell development (Stainier et al., 1995). The *Tie2* gene is required for normal vascular network formation, and for definitive hematopoiesis (Dumont et al., 1994; Sato et al., 1995; Takakura et al., 1998).

Definitive hematopoietic progenitors and stem cells have been found in several distinct sites in the embryo, including the yolk sac (Moore and Metcalf, 1970; Toles et al., 1989; Weissman et al., 1977), the umbilical and vitelline arteries, the para-aortic splanchnopleure and the aorta/genital ridge/ mesonephros (AGM) region (Dieterlen-Lièvre and Martin, 1981; Eren et al., 1987; Godin et al., 1995, 1993; Medvinsky and Dzierzak, 1996; Medvinsky et al., 1993; Müller et al., 1994; Ogawa et al., 1988; Tavian et al., 1996; Yoder et al., 1997). Some of these hematopoietic cells have been found in close association with endothelium. In humans, chicks and mice, clusters of hematopoietic cells were found associated with the endothelium on the ventral surface (floor) of the dorsal aorta (Dieterlen-Lièvre and Martin, 1981; Garcia-Porrero et al., 1995; Tavian et al., 1996). In the mouse, the clusters are found at the developmental time when long-term repopulating hematopoietic stem cells (LTR-HSCs) appear in the AGM region (Medvinsky and Dzierzak, 1996). Histological pictures have also shown clusters of hematopoietic cells budding from the endothelium of the vitelline and umbilical arteries in 9.5 dpc–11.5 dpc mouse embryos (Garcia-Porrero et al., 1995; Wood et al., 1997). Grafting experiments in chicks suggest that endothelial cells and intra-aortic hematopoietic clusters that populate the floor of the dorsal aorta share a common hemangioblast precursor in the splanchnopleural mesoderm (Pardanaud et al., 1996). More recent experiments suggest that definitive hematopoietic cells differentiate directly from an

endothelial precursor. For example, Nishikawa et al. (1998b) showed that lymphoid cells could be cultured in vitro from VE-cadherin-positive endothelial cells isolated from the yolk sac and caudal region of mouse embryos. Lineage tracing experiments demonstrated that endothelial cells in the chick aorta marked with low-density lipoproteins (LDL) coupled to DiI give rise one day later to LDL-marked hematopoietic clusters on the floor of the aorta (Jaffredo et al., 1998).

Cbfa2 and *Cbfb* encode two subunits of a core-binding factor (CBF) that is required at an early stage in definitive hematopoiesis. *Cbfa2* encodes a DNA-binding CBFα subunit, and *Cbfb* encodes the non-DNA binding CBFβ subunit. Homozygous disruption of either *Cbfa2* or *Cbfb* severely impairs definitive hematopoiesis, but does not affect primitive erythropoiesis or development of the yolk sac vasculature (Niki et al., 1997; Okuda et al., 1996; Sasaki et al., 1996; Wang et al., 1996a,b). Differentiation of all definitive hematopoietic lineages is affected, suggesting that *Cbfa2* and *Cbfb* are required at the level of definitive hematopoietic progenitors and/or stem cells.

To determine precisely when during definitive hematopoiesis *Cbfa2* and *Cbfb* are required, we identified cells expressing *Cbfa2* in developing mouse embryos, and examined the fate of these cells in *Cbfa2*-deficient embryos. We find that *Cbfa2* expression marks a transient population of endothelial cells populating the floor of the dorsal aorta in the AGM region, as well as endothelial cells in other sites where definitive hematopoietic cells are thought to emerge. Intra-aortic hematopoietic clusters in the vitelline and umbilical arteries, and on the floor of the dorsal aorta are absent in *Cbfa2*-deficient mice. We hypothesize that *Cbfa2* is required for the 'budding' of hematopoietic cells from hemogenic endothelium at these sites. *Cbfa2* also appears to be required for maintenance of *Cbfa2* expression in endothelial cells.

MATERIALS AND METHODS

Recombination constructs and targeting of ES cells

The targeting vector replaced a 10.0 kb fragment, including exons 7 and 8 of *Cbfa2*, with *lacZ* coding sequences, followed by the PGK*neo^r* gene. Nucleotides 702-970 from the pSV-β-galactosidase vector (Promega) were amplified by polymerase chain reaction (PCR), using the primers (sense) 5′-AACTGCAGTCGATCCCGTCGTTTTACAA-CA-3′ and (antisense) 5′-GTAACCGTGCATCTGCCAGT-3′. The PCR product was cleaved with *Pst*I and *Bsu*36I, and subcloned along with a *Bsu*36 I-*Bam*HI fragment from the pSV-β-galactosidase vector, containing the 3′ end of *lacZ* coding sequences plus the SV40 small T antigen and poly(A) signals, into the targeting vector. The *lacZ/neo* cassette was flanked by 5.6 and 3.7 kb of *Cbfa2* homology upstream and downstream, respectively. A thymidine kinase gene (*tk*) under the regulation of the PGK promoter was incorporated at the 3′ end of the homology region.

The targeting vector was linearized with *Not*I, electroporated into J1 ES cells, and *Cbfa2^{lz/+}* F1 mice generated by standard protocols, and as described previously (Li et al., 1992; Wang et al., 1996a,b). Genotypes were determined by β-galactosidase activity, Southern blot analysis of tail, embryo, or yolk sac DNA (Fig. 1B), or by PCR analysis using primers specific for the *lacZ* gene (5′-ACTGGCAGATGCACGGTTAC-3′ and 5′-GTGGCAACATGGA-AATCGCTG-3′).

Cbfa2^{lz/+} female mice were crossed with *Cbfa2^{rd/+}* males (Wang et al., 1996a) to generate *Cbfa2^{lz/rd}* embryos. The *Cbfa2^{lz}* allele was identified by β-galactosidase activity, and the *Cbfa2^{rd}* allele by PCR,

using a primer from within *neo* (5′-TCGCAGCGCATCGCCTTCA-3′), in conjunction with a primer from intron 4 of *Cbfa2* (5′-AGTAGATAGGTATGAGTCCC-3′). The cross was designed so that PCR detection of the *Cbfa2^{rd}* allele was not complicated by maternal contamination of fetal tissues.

Light microscopy

Embryos were dissected at various stages of gestation and processed for β-galactosidase activity, as described by Miles et al. (Miles et al., 1997). 8 μm sections of entire paraffin wax-embedded embryos were prepared, and alternate slides were counterstained with hematoxylin and eosin to facilitate tissue identification. Forty embryos from 6.5 to 10.5 dpc were analyzed.

Semi-thin sections from AGM regions were prepared by fixing 10.5 dpc *Cbfa2^{+/+}* and *Cbfa2^{lz/rd}* embryos in 3% glutaraldehyde (GTA), 2% paraformaldehyde (PF), 2.5% dimethylsulfoxide (DMSO), and 0.1% CaCl₂ buffered by 0.1 M sodium cacodylate (pH 7.4) for at least 3 hours at room temperature (RT). Samples were rinsed three times in 0.1 M sodium cacodylate containing 0.05% CaCl₂ and 0.3 M sucrose at pH 7.4, a transverse cut was made 2-3 somites caudal to the developing forelimbs, and the posterior portion of the embryo (including the AGM region) was post-fixed in 2% OsO₄ in 0.1 M sodium cacodylate/0.05% CaCl₂/0.3 M sucrose at pH 7.4 for 2 hours at RT. Samples were dehydrated through a graded series of ethanols and propylene oxide, and embedded in epon (LX112). Semi-thin sections (0.5-0.7 μm) were prepared from similar areas in each block and stained with 'Epoxy Tissue Stain' (toluidine blue and basic fuschin; Electron Microscopy Sciences, Inc.).

Ultrastructure analysis

Embryos (10.5 dpc) were isolated in ice cold PBS and fixed for 2 hours at RT in 2% PF/0.25% GTA in 0.1 M piperazine-N, N′-bis[2-ethane-sulfonic acid] (PIPES) buffer. Embryos were washed in PBS, then stained with 1 mg/ml Bluo-gal (Sigma) for 6 hours at 37°C. Samples were rinsed in PBS, a transverse cut made 2-3 somites caudal to the developing forelimbs, and the posterior portion of the embryo post-fixed in 3% GTA, 2% PF, 2.5% dimethylsulfoxide (DMSO), 0.1% CaCl₂ buffered by 0.1 M sodium cacodylate (pH 7.4) for at least 3 hours at RT. Samples were rinsed three times in 0.1 M sodium cacodylate at pH 7.4, post-fixed in 2% OsO₄, 0.1 M sodium cacodylate (pH 7.4), embedded in epon (LX112), and 0.5-0.7 μm sections prepared as described above. Semi-thin sections were lightly stained (15-30 seconds) with 'Epoxy Tissue stain'. Thin sections (60-90 nm) were prepared from each block, stained with 2% aqueous uranyl acetate (50 minutes), followed by Reynold's lead citrate (8 minutes). All electron micrographs were taken at 80 or 100 kV on a JEOL 100CX.

Methylcellulose colony forming assays

Fetal livers, vitelline and umbilical arteries/cords were dissected from 11.5 dpc embryos and digested in 0.1% collagenase (Sigma, C2674), 20% fetal calf serum (FCS) in PBS at 37°C for 1-2 hours. Cells were washed with alpha minimum essential medium (GIBCO/BRL) and plated in 35 mm suspension dishes in alpha medium containing 0.8% methylcellulose, 30% FCS, 1% bovine serum albumin, 2 mM glutamine, 0.1% 2-mercaptoethanol (Methocult; Stemcell Technologies, Vancouver). Methylcellulose medium was supplemented with 1.3% pokeweed mitogen-stimulated spleen cell conditioned medium (Stemcell Technologies), 2 units/ml erythropoietin (R&D Systems), 20 ng/ml IL-3 (R&D Systems), 50 ng/ml stem cell factor (SCF; R&D Systems), and 5 ng/ml granulocyte-macrophage colony stimulating factor (GM-CSF; R&D Systems).

FACS analysis

Livers and AGM regions from 11.5 dpc embryos, and bone marrow from adult mice were prepared and loaded with di-(β-D-galactopyranoside) (FDG) as described by Sanchez et al. (Sanchez et al., 1996). Phycoerythrin (PE)-conjugated antibodies to c-kit (2B8),

Mac-1 (M1/70), PECAM-1 (MEC13.3), and CD44 (IM7) were obtained from Pharmingen. PE-conjugated streptavidin (Pharmingen) was used to detect both biotinylated CD34 antibody (RAM34, Pharmingen) and a biotinylated anti-goat antibody (Vector Laboratories), after primary incubation with goat-anti-mouse SCF (G19, Santa Cruz Biotechnology, Inc.). FDG-loaded cells (1×10^5) from individual embryos, or pooled aliquots of cells from embryos with identical genotypes were stained with primary antibody, incubated on ice for 20 minutes, and washed with PBS/FCS. Secondary and tertiary incubations were performed when applicable, as described above. Appropriate isotype controls were used in each experiment. After the final wash, cells were resuspended in 500 µl PBS/FCS. The fluorescence created by the β-galactosidase reaction was detected on the FITC channel of a FACStar (Becton-Dickinson). PE was detected on the FL2 channel. Triple labeling of cells was performed using a Cy-Chrome (FL3) conjugated streptavidin (Pharmingen) to detect biotinylated antibodies, while PE-labeled c-kit and β-galactosidase expression were detected as described above.

RESULTS

Cbfa2 and *Cbfb* are required for definitive hematopoiesis, indicating that both subunits of the heterodimer are essential for function in vivo. Since *Cbfa2* expression appears to be more temporally and spatially restricted than that of *Cbfb* (Ogawa et al., 1993; Satake et al., 1995; Simeone et al., 1995; Wang et al., 1993), it should be the more accurate indicator of where the active heterodimer is located. We introduced a marker, the bacterial *lacZ* gene, into the *Cbfa2* locus by homologous recombination. The targeting vector replaced exons 7 and 8 of *Cbfa2* with *lacZ* coding sequences (Fig. 1A,B). The splice acceptor site from exon 7 was preserved, so that a CBFα2-β-galactosidase fusion protein would be synthesized containing the N-terminal 242 amino acids from CBFα2 (Bae et al., 1993) (including its DNA-binding domain) fused to β-galactosidase sequences. Nuclear localization sequences from CBFα2 should be contained within the fusion protein (Kanno et al., 1998), and we found β-galactosidase activity concentrated in the nucleus (Fig. 1C).

Cbfa2 expression in *Cbfa2*$^{lz/+}$ embryos is first seen at 7.5 dpc, at the neural plate stage of development (Fig. 2A), in the endoderm and some extraembryonic mesodermal cells (not shown). At 8.0-8.5 dpc, *Cbfa2* expression coalesces into a tight band encircling the yolk sac (Fig. 2B). All newly emerging primitive erythrocytes in the yolk sac express *Cbfa2* at 8.0 dpc (not shown), but by 8.5 dpc, *Cbfa2* expression declines significantly (Fig. 2C), and disappears entirely by 10.5 dpc (Fig. 3C) in all primitive erythrocytes. The ring of *Cbfa2* expression remaining at 8.5 dpc consists of punctate

expression in yolk sac endoderm, and intense expression in small numbers of endothelial cells in yolk sac capillaries, in hematopoietic cells closely associated with yolk sac endothelium, and in endothelial cells that appear to be budding into the lumina of yolk sac capillaries (Fig. 2C). *Cbfa2* is also expressed in mesenchymal cells in the distal portion of the allantois at 8.5 dpc, at the point where it joins the chorion (not shown). The allantois was recently shown to be a source of HSCs in birds (Caprioli et al., 1998). The allantois will form the body stalk, which includes the umbilical artery, a site where hematopoietic cells have also been seen histologically in mice (Garcia-Porrero et al., 1995; Wood et al., 1997).

In the 8.5 dpc embryo proper, *Cbfa2* is expressed in

Fig. 1. Generation of the *Cbfa2*^{lz} allele. (A) Targeting strategy used to replace exons 7 and 8 of the *Cbfa2* gene with *lacZ* coding sequences. Probe A was used to screen for homologous recombination events, and probe B to confirm the deletion of exon 7 sequences in *Cbfa2*$^{lz/lz}$ embryos. The expected size of the *Eco*RI restriction fragments that hybridize with probe A, and the *Spe*I fragment that hybridizes with probe B are indicated. Black regions indicate *Cbfa2* coding sequences in exon 7 and within exon 8. S, *Sal*I; E, *Eco*RI; P, *Pst*I; Sp, *Spe*I; N, *Nae*I. (B) Southern analysis of genomic DNA from 11.5 dpc embryos. (C) Predominantly nuclear localization of β-galactosidase activity in mouse embryo fibroblasts isolated from 12.5 dpc *Cbfa2*$^{lz/+}$ embryos.

endothelial cells of the vitelline artery, and in the ventral portion (floor) of the paired dorsal aortae (Fig. 2D). The vitelline artery is the caudal extension of the dorsal aorta at 8.5 dpc, connecting it to the yolk sac circulation (for a brief description of the development of the arterial system in the caudal region of the mouse embryo, see Garcia-Porrero et al., 1995). *Cbfa2* expression in the vitelline artery is restricted to its intra-embryonic portion, and is not seen in the segment of the artery that extends into the yolk sac.

Cbfa2 expression in 10.5 dpc embryos can be seen in the vitelline and umbilical arteries, the fetal liver, the AGM region, and in sites unrelated to hematopoiesis (Fig. 2E). In the vitelline (Fig. 2F) and umbilical arteries (not shown), grape-like clusters of hematopoietic cells expressing *Cbfa2* can be seen closely associated with endothelial cells in the lumen. The extraembryonic portion of these arteries from 10.5-11.5 dpc embryos gave rise to large, predominantly myeloid or mixed lineage colonies in colony forming unit culture (CFU-C) assays (Fig. 2G,H; Table 1).

Fetal livers from 10.5 dpc embryos express *Cbfa2* in the liver capsule mesoderm (Fig. 5A,B), and in hematopoietic cells (Fig. 3A). Fluorescence activated cell sorting (FACS) analysis demonstrates that CBFα2+ fetal liver and adult bone marrow cells express cell surface markers associated with definitive hematopoietic stem cells and early progenitors (Fig. 4A-C,G-I). In fetal livers from 11.5 dpc embryos, 36% of the cells co-express *Cbfa2* and CD34. The latter is expressed on fetal liver and bone marrow hematopoietic stem cells and early progenitors (Andrews et al., 1992; Katz et al., 1985; Krause et al., 1994) (Fig. 4A). 25% of fetal liver cells express both c-kit and *Cbfa2* (Fig. 4A). Sanchez et al. (1996) showed that fetal liver LTR-HSCs reside mainly in the c-kit+CD34+ population. 14% of fetal liver

cells at 11.5 dpc are in the c-kit+CD34+ population, and 90-95% of c-kit+CD34+ cells express *Cbfa2* (Fig. 4B).

Other cell surface antigens expressed on fetal liver and bone marrow CBFα2+ cells include the cell surface form of stem cell factor (SCF), which is expressed in many tissues, including CD34+ endothelial cells (Fennie et al., 1995; Fleischman et al., 1995; Matsui et al., 1990). 37% of fetal liver cells express both *Cbfa2* and SCF, and 64% of c-kit+SCF+ fetal liver cells express *Cbfa2* (Fig. 4C). CD44, a marker of definitive hematopoietic progenitor cells, is expressed on 84% of CBFα2+ fetal liver cells (Fig. 4C). Mac-1, which is expressed on macrophages, granulocytes and some LTR-HSCs (Morrison et al., 1995; Sanchez et al., 1996), is expressed on 17% of CBFα2+ cells (Fig. 4C). 55% of CBFα2+ fetal liver cells express PECAM-1 (CD31), a marker on vascular endothelial cells and early

Fig. 2. *Cbfa2* expression during mouse development in *Cbfa2lz/+* embryos. (A) *Cbfa2* expression in the extraembryonic tissue of a 7.5 dpc embryo, at the neural plate stage. (B) *Cbfa2* expression in developing blood islands at 8.5 dpc. The negative embryo on the right is a *Cbfa2+/+* littermate. (C) Detail of the yolk sac (8.5 dpc) showing *Cbfa2* expression in endothelial cells, and in hematopoietic cells closely associated with the endothelium (black arrows). Note that primitive erythrocytes express only low levels of *Cbfa2* (outlined arrows). Punctate staining is also seen in the yolk sac endoderm (e). (D) Section of an 8.5 dpc embryo showing *Cbfa2* expression in vitelline artery endothelial cells (v), ventral walls of the paired dorsal aortae (a), and yolk sac (y) vessels. Note that *Cbfa2* expression is in the intraembryonic segment (open arrow), but not the extraembryonic segment (black arrow) of the vitelline artery. (E) View of a 10.5 dpc embryo showing *Cbfa2* expression in the vitelline (v) and umbilical (u) arteries, AGM region (agm), and fetal liver (fl). Expression is also seen in the olfactory epithelium (o), spinal ganglia (g), and maxillary processes (m). Expression in external genitalia is not visible from this angle. (F) View of the vitelline artery intra-abdominal segment (10.5 dpc) with a hematopoietic cell cluster expressing *Cbfa2*.
(G,H) Cytocentrifuge preparations of myeloid (G) and mixed lineage (H) colonies from in vitro cultures of umbilical arteries from 11.5 dpc *Cbfa2+/+* embryos, showing neutrophils (n), macrophages (m), eosinophils (eo), and enucleated erythrocytes (er) (Wright Giemsa stain).

hematopoietic precursor cells (Albelda et al., 1990; Watt et al., 1993) (Fig. 4C).

Cbfa2 is expressed at 10.5 dpc in the ventral portion of the dorsal aorta within the AGM region (Fig. 3A,B). The anterior and posterior boundaries of *Cbfa2* expression in the AGM region coincide with the location of the mesonephros, but do not extend in the rostral direction into the region flanked by pronephros. Four discrete cell types in the AGM region express *Cbfa2*: mesenchymal cells, endothelial cells, small numbers of hematopoietic cells in the lumen (Fig. 3C), and a few cells in the mesonephros (not shown). Almost all endothelial cells in the floor of the dorsal aorta express *Cbfa2*, while very few endothelial cells in the roof of the aorta express *Cbfa2*.

Cbfa2 expression in endothelial cells was confirmed by ultrastructural analysis, using a β-galactosidase substrate (Bluo-gal), the product of which forms an electron dense precipitate that adheres to cell membranes (Weis et al., 1991) (Fig. 3E). CBFα2⁺ cells in the floor of the dorsal aorta participate in the formation of zonula occludens type (tight) junctions to adjacent endothelial cells. Many CBFα2⁺ endothelial cells in the floor of the aorta have a very rounded appearance, and appear to be budding into the lumen of the aorta. In multiple sections from six embryos we failed to identify any endothelial cells in mitosis, suggesting this region of the dorsal aorta may expand via recruitment of cells from the surrounding mesenchyme.

FACS analysis of cells isolated from the AGM region of 11.5 dpc embryos shows that 10% of CBFα2⁺ cells express CD34 (Fig. 4D), and approximately 27% of CBFα2⁺ cells express c-kit. LTR-HSCs isolated from the AGM region of 11 dpc embryos reside in the c-kit⁺CD34⁺ population (Sanchez et al., 1996). Within the c-kit⁺CD34⁺population, 35% express *Cbfa2* (Fig. 4E).

Emergence of LTR-HSCs from the AGM region peaks at approximately 11 dpc in the mouse (Sanchez et al., 1996). We examined AGM regions from 14.5 dpc *Cbfa2$^{lz/+}$* embryos to determine whether *Cbfa2* expression in endothelium persists at later stages of development. *Cbfa2* expression in the dorsal aorta of 14.5 dpc embryos was found immediately rostral to the bifurcation of the dorsal aorta into the iliac arteries. The dorsal aorta elongates in the caudal direction as the embryo grows, and *Cbfa2* expression at all stages examined (8.5-14.5 dpc) appears to coincide with the actively growing caudal portion of the aorta. Histological sections show that *Cbfa2* expression in the vicinity of the dorsal aorta at 14.5 dpc is restricted to mesenchymal cells (Fig. 3D). The endothelium, which at this time is separated from the mesenchyme by a layer of smooth muscle, does not express *Cbfa2*. No budding of hematopoietic cells from the endothelium is apparent at 14.5 dpc. *Cbfa2* expression in the umbilical cord of 17.5 dpc

Fig. 3. Detail of *Cbfa2* expression in the AGM region. (A) Section of a *Cbfa2$^{lz/+}$* embryo (10.5 dpc) showing *Cbfa2* expression in the ventral wall of the dorsal aorta (a), and in fetal liver hematopoietic cells (fl). (B) *Cbfa2* expression in the ventral para-aortic mesenchyme. (C) View of the dorsal aorta ventrolateral wall showing *Cbfa2* expression in some endothelial cells (closed arrows), para-aortic mesenchyme (open arrows), and circulating hematopoietic cells (c). Note that most circulating blood cells (primitive erythrocytes) no longer express *Cbfa2*. The few circulating *Cbfa2*-positive cells presumably represent definitive hematopoietic progenitors, and display blast-like features in sections counterstained with hematoxylin and eosin (not shown). (D) View of the dorsal aorta (a) rostral to its bifurcation into iliac arteries, from a *Cbfa2$^{lz/+}$* embryo (14.5 dpc), showing *Cbfa2* expression confined to the para-aortic mesenchyme. The rounded morphology of endothelial cells is caused by muscle contraction following fixation. (E) Electron photomicrograph of the dorsal aorta ventral wall of a *Cbfa2$^{lz/+}$* embryo (10.5 dpc) showing the Bluo-gal reaction product (thin dark precipitate) outlining many endothelial cells (arrows), and some subendothelial cells (s). Endothelial cells expressing *Cbfa2* are connected to adjacent endothelial cells (*Cbfa2* positive and negative) by tight junctions (asterisks, also see enlarged inset). Note the protrusion of many *Cbfa2*-positive endothelial cells into the lumen (L), as well as the underlying cystic separation in some (o), suggesting progressive detachment from the aortic wall.

Liver

AGM

embryos was also confined to the mesenchyme (not shown). Therefore, endothelial cells that express *Cbfa2* appear only transiently during development, coincident with the emergence of definitive hematopoietic progenitor and stem cells.

Cbfa2 is required for the formation of intra-aortic hematopoietic clusters

To pinpoint when during hematopoiesis *Cbfa2* is required, we crossed *Cbfa2$^{lz/+}$* mice with mice heterozygous for a nonfunctional *Cbfa2* allele that lacks exon 5 (*Cbfa2$^{rd/+}$*) (Wang et al., 1996a). Neither fetal livers nor the vitelline and umbilical arteries from 11.5 dpc *Cbfa2$^{lz/rd}$* embryos gave rise to definitive hematopoietic colonies in CFU-C assays (Table 1). Therefore, the *Cbfa2^{lz}* allele, which lacks coding sequences for the CBFα2 C terminus (including the transactivation domain (Kanno et al., 1998)), is a non-functional allele. We compared the histology of normal (*Cbfa2$^{lz/+}$*) and *Cbfa2*-deficient (*Cbfa2$^{lz/rd}$*) embryos. All embryos contain only one copy of the *Cbfa2^{lz}* allele, thus β-galactosidase expression levels can be directly compared.

Fig. 4. Surface antigens on *Cbfa2*-positive cells from the fetal liver and AGM region of 11.5 dpc mouse embryos. (A) Expression on fetal liver cells. Data are presented as FACS dot plots, and percentages of cells in each quadrant are indicated. Isotype control antibodies (PE and Cy) and FDG (FITC) substrate double staining are shown for fetal livers from *Cbfa2$^{+/+}$* littermates. Triple staining was performed with FDG (FITC) to detect CBFα2-βgal expression, Cy-streptavidin to detect biotinylated antibodies to CD34 and SCF, and PE directly coupled to an anti-c-kit antibody. Analysis was performed on 10^5 cells from pooled fetal livers isolated from *Cbfa2$^{lz/+}$* embryos, and data from one representative sample is shown. The mean values (range in parentheses) of 5-12 independent samples are: c-kit$^+$CBFα2-βgal$^+$ 24.1% (18.6%-27.5%); CD34$^+$CBFα2-βgal$^+$ 34.4% (33.1%-36.5%); SCF$^+$CBFα2-βgal$^+$ 35.0% (33.2%-36.4%). (B) Triple staining was performed on fetal liver cells as described in A, and the c-kit$^+$CD34$^+$ and c-kit$^+$SCF$^+$ gated populations in the upper right quadrant analyzed for CBFα2-βgal expression. The average number of c-kit$^+$CD34$^+$ cells was 12.8% (8.8%-16.5%), and c-kit$^+$SCF$^+$ cells was 16.7% (12.2%-20.6%). Percentages of CBFα2-βgal-positive cells within the c-kit$^+$CD34$^+$ and c-kit$^+$SCF$^+$ populations are indicated. (C) Isotype control antibodies (PE) and FDG (FITC) substrate double staining are shown for pooled fetal livers from *Cbfa2$^{+/+}$* embryos. Mean values (range in parentheses) of 5-12 independently pooled fetal liver samples from *Cbfa2$^{lz/+}$* embryos are: CD44$^+$CBFα2-βgal$^+$ 58.4% (55.3%-61.2%); Mac-1$^+$CBFα2-βgal$^+$ 9.5% (8.3%-10.6%); PECAM-1$^+$CBFα2-βgal$^+$ 30.8% (18.0%-42.1%). (D) AGM cells. Experiments were performed as described in A. Mean percentages: c-kit$^+$CBFα2-βgal$^+$ 2.5% (1.6%-3.7%); CD34$^+$CBFα2-βgal$^+$ 6.1% (4.6%-8.2%); SCF$^+$CBFα2-βgal$^+$ 8.8% (6.3%-11.3%). (E) Triple staining of AGM cells, as described in B. The average number of c-kit$^+$CD34$^+$ cells was 5.9% (4.2%-8.0%), and of c-kit$^+$SCF$^+$ cells was 7.8% (6.5%-10.0%). (F) AGM cells, as in C. Mean values (range in parentheses): CD44$^+$CBFα2-βgal$^+$ 2.4% (1.9%-2.9%); Mac-1$^+$CBFα2-βgal$^+$ 2.5% (2.1%-3.1%); PECAM-1$^+$CBFα2-βgal$^+$ 3.4% (3.0%-4.0%). (G) Adult bone marrow cells. Experiments were performed as described in A. Mean percentages: c-kit$^+$CBFα2-βgal$^+$ 7.6% (6.6%-9.6%); CD34$^+$CBFα2-βgal$^+$ 5.4% (4.2%-7.1%); SCF$^+$CBFα2-βgal$^+$ 22.9% (13.6%-35.8%). (H) Triple staining of bone marrow cells, as described in B. The average number of c-kit$^+$CD34$^+$ cells was 2.3% (1.9%-2.7%), and of c-kit$^+$SCF$^+$ cells was 3.7% (2.9%-5.4%). (I) Bone marrow cells, as in C. Mean values (range in parentheses): CD44$^+$CBFα2-βgal$^+$ 83.2% (79.6%-86.5%); Mac-1$^+$CBFα2-βgal$^+$ 64.9% (53.9%-72.6%); PECAM-1$^+$CBFα2-βgal$^+$ 12.4% (11.6%-13.7%).

Table 1. Colonies arising from fetal liver, vitelline artery and umbilical artery hematopoietic progenitors isolated from 11.5 dpc *Cbfa2+/+* and *Cbfa2lz/rd* embryos

| | Fetal livers | | | | Vitelline and umbilical arteries* | | | | |
| | | Colony number per embryo‡ | | | | | Colony number per embryo‡ | | |
Genotype	Embryos analyzed	E	M	Mix	Embryos analyzed	Artery§	E¶	M	Mix
Cbfa2+/+	4	105 (37)	373 (105)	248 (37)	9	Umbilical	0	29 (10)	3 (2)
						Vitelline	0	29 (15)	6 (5)
Cbfa2lz/rd	10	0	0	0	5	Umbilical	0	0	0
						Vitelline	0	0	0

*The extraembryonic portions (between the yolk sac and embryo proper) of the vitelline and umbilical arteries, representing approximately 10^4 cells, were dissected and analyzed.

‡Colonies (>30 cells in size) were scored on days 7-8 of incubation. E, erythroid colonies; M, myeloid colonies; Mix, erythroid-myeloid mixed colonies. Average number of colonies per embryo is indicated, followed by standard deviation in parentheses.

§Umbilical artery and vitelline arteries were isolated from the same embryos.

¶Small numbers of erythroid colonies were seen in separate experiments from pooled 10.5 dpc and 11.5 dpc *Cbfa2+/+* embryos (not shown).

Fetal livers of 10.5 dpc *Cbfa2lz/rd* embryos contain CBFα2+ mesenchymal cells, but no CBFα2+ hematopoietic cells (Fig. 5B). FACS analysis of 11.5 dpc *Cbfa2lz/rd* embryos indicates severe depletion of CD44+ hematopoietic progenitors (Fig. 6A). Significant decreases are also seen in the proportions of CBFα2+c-kit+, CBFα2+CD34+, CBFα2+SCF+, and CBFα2+CD44+ fetal liver cells.

The absence of fetal liver hematopoiesis does not appear to result from failure of definitive hematopoietic cells to home properly to the fetal liver, since hematopoietic cells expressing *Cbfa2* are also undetectable in circulating blood (not shown). Rather, there appears to be a defect in the formation of intra-aortic hematopoietic clusters. No clusters of hematopoietic cells are present in the vitelline arteries of 10.5 dpc *Cbfa2lz/rd* embryos (Fig. 5F). Furthermore, both the numbers of endothelial cells expressing *Cbfa2*, and the intensity of *Cbfa2* expression in endothelial cells is dramatically reduced in the vitelline (Fig. 5F) and umbilical (not shown) arteries. This defect is not caused by failure of CBFα2+ endothelial cells to migrate to these arteries, since CBFα2+ endothelial cells are present one day earlier, at 9.5 dpc (Fig. 5D). *Cbfa2* expression in yolk sac endothelial cells is, however, absent in 9.5 dpc *Cbfa2lz/rd* embryos, and no CBFα2+ hematopoietic cells are visible (Fig. 5H).

Significant defects are also observed in the AGM region of *Cbfa2* deficient embryos. At 9.5 dpc, endothelial cells

and para-aortic mesenchymal cells expressing *Cbfa2* are present in the floor of the dorsal aorta in both *Cbfa2lz/+* and *Cbfa2lz/rd* embryos (Fig. 7A,B). However, whereas by 10.5 dpc *Cbfa2* expression has intensified in endothelial cells of *Cbfa2lz/+* embryos and hematopoietic cells are apparent, *Cbfa2*

Fig. 5. Fate of CBFα2+ cells in *Cbfa2*-deficient embryos. (A,B) Views of fetal livers from *Cbfa2lz/+* (A) and *Cbfa2lz/rd* (B) embryos (10.5 dpc) showing the presence (A) and absence (B) of hematopoietic cells expressing *Cbfa2* within the liver sinusoids. Note the positive staining in the liver capsule mesoderm in both embryos. (C,D) View of the vitelline arteries from *Cbfa2lz/+* (C) and *Cbfa2lz/rd* (D) embryos (9.5 dpc) showing endothelial cell expression. (E,F) Detail of vitelline arteries of *Cbfa2lz/+* (E) and *Cbfa2lz/rd* (F) embryos (10.0 dpc), showing strong *Cbfa2* expression in both endothelial cells and hematopoietic clusters (E), and minimal expression in *Cbfa2lz/rd* embryos (F). (G,H) View of yolk sacs showing strong *Cbfa2* expression in endothelial and hematopoietic cells in *Cbfa2lz/+* embryos (G), and its absence in *Cbfa2lz/rd* embryos (H) (9.5 dpc).

Fig. 6. Expression of hematopoietic markers in 11.5 dpc *Cbfa2^lz/+* and *Cbfa2^lz/rd* embryos. (A) Fetal livers, analyzed as described in Fig. 4. Data are from individual, representative embryos. The average values (range in parentheses) for 8-13 embryos of CBFα2-βgal⁺ cells expressing other cell surface markers (upper right quadrants) are as follows: *Cbfa2^lz/+*; c-kit⁺ 22.6% (19.1%-28.0%), CD34⁺ 42.0% (37.6%-47.6%), SCF⁺ 40.3% (36.1%-40.9%), CD44⁺ 56.6% (55.1%-63.6%). *Cbfa2^lz/rd*; c-kit⁺ 6.2% (4.8%-8.2), CD34⁺ 16.4% (14.5%-18.3%), SCF⁺ 13.6% (11.1%-18.3), CD44⁺ 1.7% (0.8%-3.1%). The differences between *Cbfa2^lz/+* and *Cbfa2^lz/rd* embryos in all double positive populations was significant at t=0.01, as determined by a two tailed t-test. (B) AGM regions from individual embryos. Average values for CBFα2-βgal double positive cells (upper right quadrants) are as follows: *Cbfa2^lz/+*; c-kit⁺ 3.4% (1.2%-4.7%), CD34⁺ 8.9% (5.4%-15.1%), SCF⁺ 4.8% (2.2%-6.7%), CD44⁺ 3.5% (1.8%-4.7%). *Cbfa2^lz/rd*; c-kit⁺ 2.0% (1.1%-2.8%), CD34⁺ 8.2% (7.5%-9.8%), SCF⁺ 4.2% (3.5%-4.8%), CD44⁺ 1.6% (1.5%-2.0%).

expression fades significantly in endothelial cells of *Cbfa2^lz/rd* embryos (Fig. 7C,D). Endothelial cells in the floor of the dorsal aorta in *Cbfa2^lz/rd* embryos are relatively flat and elongated (Fig. 7H-I), compared with those in *Cbfa2^lz/+* embryos (Figs 7G, 3E). There is also significant crowding of para-aortic mesenchymal cells immediately adjacent to the ventral endothelium in *Cbfa2^lz/rd* embryos that is not seen in more dorsal sections of the aorta, nor in *Cbfa2^lz/+* embryos (Fig. 7E,F and G-H). The mesenchymal cells are elongated and flattened and in close

contact with the overlying endothelium (Fig. 7H,I), but do not form desmosomes or junctional complexes with the endothelium (not shown).

The numbers of CBFα2⁺c-kit⁺, CBFα2⁺CD34⁺, CBFα2⁺SCF⁺, and CBFα2⁺CD44⁺ cells in AGM regions from *Cbfa2^lz/+* and *Cbfa2^lz/rd* embryos are not statistically different (Fig. 6B). The presence of CBFα2⁺ cells in the AGM region that express c-kit, CD34 and SCF suggests that *Cbfa2* is not required for the expression of these three cell surface markers.

DISCUSSION

Cbfa2 is required for the differentiation of all definitive hematopoietic cells, but not for primitive erythropoiesis. Here we show that *Cbfa2* is expressed in a small, transient population of endothelial cells in the yolk sac, the vitelline and umbilical arteries, and in the floor of the dorsal aorta. Soon after *Cbfa2* is expressed in these sites, hematopoietic clusters appear that are closely associated with *Cbfa2*-positive endothelium. The timing of *Cbfa2* expression and appearance of intra-aortic hematopoietic clusters parallels the emergence of definitive hematopoietic cells, as detected previously by histology and in vivo functional analyses (Garcia-Porrero et al., 1995; Godin et al., 1995; Medvinsky and Dzierzak, 1996; Müller et al., 1994). For example, definitive hematopoietic progenitor cells with B-lymphoid potential emerge autonomously at 8.5 dpc in mice, prior to the establishment of embryonic circulation, both in the yolk sac and the para-aortic splanchnopleure, the latter of which includes the paired dorsal aortae and intraembryonic portion of the vitelline artery (Godin et al., 1995). The first long-term repopulating HSCs with the potential to engraft irradiated adult recipients emerge autonomously within the AGM region at 10.0 dpc. (Medvinsky and Dzierzak, 1996; Müller et al., 1994). *Cbfa2* expression is apparent as early as 8.5 dpc in endothelial cells lining the vitelline artery and in the floor of the dorsal aortae. *Cbfa2* expression in mesenchymal cells at the distal tip of the allantois at 8.5 dpc precedes

formation of the umbilical cord and later endothelial cell expression at that site. Clearly demarcated regions of *Cbfa2* expression are thus present as early as 8.5 dpc in all sites where definitive hematopoietic cells later emerge, supporting the hypothesis that definitive hematopoietic progenitors and/or

Fig. 7. Defects in the AGM region of *Cbfa2^{lz/rd}* embryos. (A,B) Views of the dorsal aorta ventral wall showing endothelial cell *Cbfa2* expression in both *Cbfa2^{lz/+}* (A) and *Cbfa2^{lz/rd}* (B) embryos (9.5 dpc). (C,D) High power views of the dorsal aorta ventral wall in *Cbfa2^{lz/+}* (C) and *Cbfa2^{lz/rd}* (D) embryos (10.0 dpc), showing *Cbfa2* expression in the para-aortic mesenchyme in both embryos, endothelial cell expression in the *Cbfa2^{lz/+}* embryo, and reduced endothelial cell expression in the *Cbfa2^{lz/rd}* embryo. (E,F) Comparative semi-thin (0.6 μm) sections through the AGM regions of *Cbfa2^{+/+}* (E) and *Cbfa2^{lz/rd}* (F) embryos (10.5 dpc), showing the relative cellular accumulation throughout the para-aortic mesenchyme in *Cbfa2^{lz/rd}* embryos (arrows) and the absence of accumulation in *Cbfa2^{+/+}* embryos (see also G,H). (G,H) Comparative high power views of the para-aortic AGM regions of *Cbfa2^{lz/+}* and *Cbfa2^{lz/rd}* embryos (10.5 dpc) showing the Bluo-gal reaction product (dark blue precipitate on cell membranes) in both endothelial and subendothelial cells. Note the relatively flattened appearance of endothelial cells in *Cbfa2^{lz/rd}* embryos (H), most of which do not express *Cbfa2*, as well as the subendothelial accumulation of *Cbfa2*-positive cells throughout the para-aortic mesenchyme. Cells closer to the coelomic epithelium (not shown) tend to orient their long axes perpendicular to the endothelium (arrows), suggestive of movement towards the aortic wall. In contrast, *Cbfa2*-positive cells closer to the aortic wall orient their long axes parallel to the endothelium, suggesting sub-endothelial accumulation. (I) Electron micrograph of the region outlined in H showing few positive cells in the aortic endothelium, the lack of underlying cystic separation, and the concentration of para-aortic cells with their long axes parallel to the endothelium (asterisks).

stem cells emerge autonomously from distinct sites in the embryo.

Cbfa2 appears to be required for budding of hematopoietic cells from hemogenic endothelium

Jaffredo et al. (1998) recently showed that CD45⁻ endothelial cells in the chick embryo, labeled with DiI-coupled LDL, give rise to LDL-labeled, CD45⁺ intra-aortic hematopoietic clusters, demonstrating a precursor/progeny relationship between endothelial cells and intra-aortic hematopoietic clusters. Here we show that *Cbfa2* is expressed in endothelial cells prior to the emergence of intra-aortic hematopoietic cells and clusters, and is required for the formation of these hematopoietic cells. Taken together, the data suggest that *Cbfa2* is required for the budding of hematopoietic cells from a definitive hemogenic endothelium. We envision that *Cbfa2* acts as a molecular switch specifying the conversion from an endothelial to hematopoietic cell fate.

Disruption of the *Cbfa2* gene also impairs the maintenance of *Cbfa2* expression in endothelium. Endothelial cells expressing *Cbfa2* appear in the arteries of *Cbfa2* deficient embryos by 9.5 dpc, but a marked decline in *Cbfa2* expression occurs soon thereafter. The reasons for this decline are unclear. One possible explanation is that further incorporation of CBFα2⁺ endothelial cells into these arteries is impaired, which is suggested by the significant accumulation of CBFα2⁺ para-aortic mesenchymal cells in *Cbfa2*-deficient embryos. The dorsal aorta, vitelline and umbilical arteries in *Cbfa2*-deficient embryos may continue to expand via selective incorporation of CBFα2⁻ cells, thereby diluting out the contribution from CBFα2⁺ cells. Another possibility is that the protein product of the *Cbfa2* gene may positively regulate *Cbfa2* expression. The human *Cbfa2* gene (*CBFA2*, or *AML1*) contains two promoters, one of which has three potential CBF binding sites (Ghozi et al., 1996). *Cbfa2* may contain a promoter active in hemogenic endothelial cells that initiates transcription of the gene. Subsequent maintenance of *Cbfa2* expression in hemogenic endothelial cells, and stable commitment of these cells to the hematopoietic lineage may require the active CBFα2:CBFβ heterodimer.

Cbfa2 expression may mark cells derived from definitive hemangioblasts in the splanchnopleural mesoderm

Fate mapping studies in birds demonstrated that intra-aortic hematopoietic clusters and endothelial cells that populate the floor of the dorsal aorta differentiate from the splanchnopleural mesoderm, presumably from hemangioblasts in the para-aortic mesenchyme (Pardanaud and Dieterlen-Lièvre, 1993; Pardanaud et al., 1996, 1989). Cells lining the roof of the aorta differentiate from angioblasts in the somatopleural mesoderm committed to the endothelial lineage. *Cbfa2* is the first marker that differentiates between endothelial cells in the roof and floor of the dorsal aorta, and may specifically mark endothelial cells and hematopoietic cells derived from putative hemangioblasts in the splanchnopleural mesoderm. Many cells in the ventral para-aortic mesenchyme also express *Cbfa2*, some or all of which may be definitive hemangioblasts.

The hemangioblast is most commonly described as a mesenchymal precursor capable of differentiating directly into either or both endothelial and hematopoietic cells. For example, Choi et al. (1998) showed that nonadherent blast colony-forming cells generated from mouse embryonic stem cells could give rise to either or both endothelial cells and hematopoietic progenitors, and suggested that the blast colony-forming cells are hemangioblasts. Eichmann et al. (1997) demonstrated that Flk-1⁺ mesodermal cells isolated from the posterior area of presomitic chick embryos could be differentiated into Flk-1⁺ endothelial cells or Flk-1⁻ hematopoietic cells when cultured in vitro in the presence or absence of vascular endothelial growth factor, respectively. However, we and others (Garcia-Porrero et al., 1995; Jaffredo et al., 1998) describe what appear to be newly emerging hematopoietic cells in the dorsal aorta and vitelline arteries that are connected via tight junctions to adjacent cells. These cells form an integral part of the endothelium lining the lumen of these arteries, and by this criterion are bona fide endothelial cells, forming a hemogenic endothelium. Thus, we and others (Jaffredo et al., 1998; Nishikawa et al., 1998b) propose that the differentiation of at least some definitive hematopoietic progenitors and/or stem cells from 'definitive hemangioblasts' appears to involve an endothelial intermediate. This process may differ from that by which the first wave of primitive erythrocytes and endothelial cells develop. Thus, the two views of differentiation from the hemangioblast are not necessarily incompatible.

The yolk sac gives rise to both primitive erythrocytes and progenitors for definitive hematopoietic cells. *Cbfa2* expression in the primitive erythroid lineage is quite transient, and by 8.5 dpc has largely declined. Thereafter, *Cbfa2* is expressed in a punctate pattern in the yolk sac, in a small population of endothelial cells, in hematopoietic cells in close contact with the endothelium, and in hematopoietic cells that appear to be budding from the endothelium. Young et al. (Young et al., 1995) described a small population of CD34⁺ hematopoietic cells in the yolk sac in close contact with the endothelium, although details of hematopoietic budding would have been difficult to see since all yolk sac endothelial cells express CD34. In *Cbfa2*-deficient embryos, the first burst of *Cbfa2* expression and development of primitive erythrocytes from the extraembryonic mesodermal mass occurs normally, but the subsequent budding of hematopoietic cells from endothelial cells lining yolk sac capillaries is impaired. We propose that at least some definitive hematopoietic progenitors in the yolk sac may differentiate via an endothelial cell intermediate in yolk sac capillaries, by a process similar to that observed in the vitelline and umbilical arteries and in the AGM region.

REFERENCES

Albelda, S. M., Oliver, P. D., Romer, L. H. and Buck, C. A. (1990). EndoCAM: a novel endothelial cell-cell adhesion molecule. *J. Cell Biol.* **110,** 1227-1237.

Andrews, R. G., Bryant, E. M., Bartelmez, S. H., Muirhead, D. Y., Knitter, G. H., Bensinger, W., Strong, D. M. and Bernstein, I. D. (1992). CD34+ marrow cells, devoid of T and B lymphocytes, reconstitute stable lymphopoiesis and myelopoiesis in lethally irradiated allogeneic baboons. *Blood* **80,** 1693-1701.

Augustin, H. G., Kozian, D. H. and Johnson, R. C. (1994). Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes. *BioEssays* **16,** 901-906.

Bae, S. C., Yamaguchi-Iwai, Y., Ogawa, E., Maruyama, M., Inuzuka, M., Kagoshima, H., Shigesada, K., Satake, M. and Ito, Y. (1993). Isolation of PEBP2αB cDNA representing the mouse homolog of human acute myeloid leukemia gene, *AML1*. *Oncogene* **8,** 809-814.

Caprioli, A., Jaffredo, T., Gautier, R., Dubourg, C. and Dieterlen-Lièvre, F. (1998). Blood-borne seeding by hematopoietic and endothelial precursors from the allantois. *Proc. Natl. Acad. Sci. USA* **95,** 1641-1646.

Choi, K., Kennedy, M., Kazarov, A., Papadimitriou, J. C. and Keller, G. (1998). A common precursor for hematopoietic and endothelial cells. *Development* **125,** 725-732.

Dieterlen-Lièvre, F. and Martin, C. (1981). Diffuse intraembryonic hematopoiesis in normal and chimeric avian development. *Dev. Biol.* **88,** 180-191.

Dumont, D. J., Gradwohl, G., Fong, G.-H., Puri, M. C., Gertsenstein, M., Auerbach, A. and Breitman, M. L. (1994). Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, *tek*, reveal a critical role in vasculogenesis of the embryo. *Genes. Dev.* **8,** 1897-1909.

Eren, R., Zharhary, D., Abel, L. and Globerson, A. (1987). Ontogeny of T cells: development of pre-T cells from fetal liver and yolk sac in the thymus microenvironment. *Cell. Immunol.* **108,** 76-84.

Eichmann, A., Corbel, C., Natif, V., Vaigot, P., Breant, C., and Le Dourarin, N. M. (1997). Ligand-dependent development of the endothelial and hemopoietic lineage from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2. *Proc. Natl. Acad. Sci. USA* **94,** 5141-5146.

Fennie, C., J., C., Dowbenko, D., Young, P. and Lasky, L. A. (1995). CD34+ endothelial cell lines derived from murine yolk sac induce the proliferation and differentiation of yolk sac CD34+ hematopoietic progenitors. *Blood* **86,** 4454-4467.

Fleischman, R. A., Simpson, F., Gallardo, T., Jin, X.-L. and Perkins, S. (1995). Isolation of endothelial-like stromal cells that express Kit ligand and support in vitro hematopoiesis. *Exp. Hematol.* **23,** 1407-1416.

Garcia-Porrero, J. A., Godin, I. E. and Dieterlen-Lièvre, F. (1995). Potential intraembryonic hemogenic sites at pre-liver stages in the mouse. *Anat. Embryol.* **192,** 425-435.

Ghozi, M. C., Bernstein, Y., Negreanu, V., Levanon, D. and Groner, Y. (1996). Expression of the human acute myeloid leukemia gene *AML1* is regulated by two promoter regions. *Proc. Natl. Acad. Sci. USA* **93,** 1935-1940.

Godin, I. E., Garcia-Porrero, J. A., Coutinho, A., Dieterlen-Lièvre, F. and Marcos, M. A. R. (1993). Para-aortic splanchnopleura from early mouse embryos contain B1a cell progenitors. *Nature* **364,** 67-70.

Godin, I., Dieterlen-Lièvre, F. and Cumano, A. (1995). Emergence of multipotent hematopoietic cells in the yolk sac and paraaortic splanchnopleura of 8.5 dpc mouse embryos. *Proc. Natl. Acad. Sci. USA* **92,** 773-777.

Haar, J. L. and Ackerman, G. A. (1971). A phase and electron microscopic study of vasculogenesis and erythropoiesis in the yolk sac of the mouse. *Anat. Rec.* **170,** 199-223.

Jaffredo, T., Gautier, R., Eichmann, A. and Dieterlen-Lièvre, F. (1998). Intraaortic hemopoietic cells are derived from endothelial cells during ontogeny. *Development* **125,** 4575-4583.

Kanno, T., Kanno, Y., Chen, L.-F., Ogawa, E., Kim, W.-Y. and Ito, Y. (1998). Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor α subunit revealed in the presence of the β subunit. *Mol. Cell. Biol.* **18,** 2444-2454.

Katz, F., Tindle, R. W., Sutherland, D. R. and Greaves, M. F. (1985). Identification of a membrane glycoprotein associated with hematopoietic progenitor cells. *Leuk. Res.* **9,** 191-198.

Krause, D. S., Ito, T., Fackler, M. J., Smith, O. M., Collector, M., Sharkis, S. J. and May, W. S. (1994). Characterization of murine CD34, a marker for hematopoietic progenitor and stem cells. *Blood* **84,** 691-701.

Li, E., Bestor, T. H. and Jaenisch, R. (1992). Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. *Cell* **69,** 915-926.

Matsui, Y., Zsebo, K. M. and Hogan, B. (1990). Embryonic expression of a haematopoietic growth factor encoded by the Sl locus, the ligand for c-kit. *Nature* **347,** 667-669.

Medvinsky, A. L., Samoylina, N. L., Müller, A. M. and Dzierzak, E. A. (1993). An early pre-liver intra-embryonic source of CFU-S in the developing mouse. *Nature* **364,** 64-66.

Medvinsky, A. and Dzierzak, E. (1996). Definitive hematopoiesis is autonomously initiated by the AGM region. *Cell* **86,** 897-906.

Miles, C., Sanchez, M.-J., Sinclair, A. and Dzierzak, E. (1997). Expression of the Ly-6E.1 (Sca-1) transgene in adult hematopoietic stem cells and the developing mouse embryo. *Development* **124,** 537-547.

Moore, M. A. S. and Metcalf, D. (1970). Ontogeny of the haemopoietic system: yolk sac origin of *in vivo* and *in vitro* colony forming cells in the developing mouse embryo. *Br. J. Haematol.* **18,** 279-296.

Morrison, S. J., Hemmati, H. D., Wandycz, A. M. and Weissman, I. L. (1995). The purification and characterization of fetal liver hematopoietic stem cells. *Proc. Natl. Acad. Sci. USA* **92,** 10302-10306.

Müller, A. M., Medvinsky, A., Strouboulis, J., Grosveld, F. and Dzierzak, E. (1994). Development of hematopoietic stem cell activity in the mouse embryo. *Immunity* **1,** 291-301.

Murray, P. D. F. (1932). The development 'in vitro' of blood of the early chick embryo. *Proc. Roy. Soc. London* **11,** 497-521.

Niki, M., Okada, H., Takano, H., Kuno, J., Tani, K., Hibino, H., Asano, S., Ito, Y., Satake, M. and Noda, T. (1997). Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding subunit of the transcription factor, polyomavirus enhancer binding protein 2/core binding factor. *Proc. Natl. Acad. Sci. USA* **94,** 5697-5702.

Nishikawa, S.-I., Nishikawa, S., Hirashima, M., Matsuyoshi, N. and Kodama, H. (1998a). Progressive lineage analysis by cell sorting and culture identifies FLK1+VE-cadherin+ cells at a diverging point of endothelial and hematopoietic lineages. *Development* **125,** 1747-1757.

Nishikawa, S.-I., Nishikawa, S., Kawamoto, H., Yoshida, H., Kizumoto, M., Kataoka, H. and Katsura, Y. (1998b). In vitro generation of lymphohematopoietic cells from endothelial cells purified from murine embryos. *Immunity* **8,** 761-769.

Ogawa, E., Inuzuka, M., Maruyama, M., Satake, M., Naito-Fujimoto, M., Ito, Y. and Shigesada, K. (1993). Molecular cloning and characterization of PEBP2β, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2α. *Virology* **194,** 314-331.

Ogawa, M., Nishikawa, S., Ikuta, K., Yamamura, F., Naito, M., Takahashi, K. and Nishikawa, S. (1988). B cell ontogeny in murine embryo studied by a culture system with the monolayer of a stromal cell clone, ST2: B cell progenitor develops first in the embryonal body rather than in the yolk sac. *EMBO J.* **7,** 1337-1343.

Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G. and Downing, J. R. (1996). AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. *Cell* **84,** 321-330.

Pardanaud, L. and Dieterlen-Lièvre, F. (1993). Emergence of endothelial and hemopoietic cells in the avian embryo. *Anat. Embryol.* **187,** 107-114.

Pardanaud, L., Yassine, F. and Dieterlen-Lièvre, F. (1989). Relationship between vasculogenesis, angiogenesis and hemapoiesis during avian ontogeny. *Development* **105,** 473-485.

Pardanaud, L., Luton, D., Prigent, M., Bourcheix, L.-M., Catala, M. and Dieterlen-Lièvre, F. (1996). Two distinct endothelial lineages in ontogeny, one of them related to hemopoiesis. *Development* **122,** 1363-1371.

Robb, L., Lyons, I., Li, R., Hartley, L., Köntgen, F., Harvey, R. P., Metcalf, D. and Begley, C. G. (1995). Absence of yolk sac hematopoiesis from mice with a targeted disruption of the *scl* gene. *Proc. Natl. Acad. Sci. USA* **92,** 7075-7079.

Sabin, F. R. (1920). Studies on the origin of blood vessels and of red corpuscles as seen in the living blastoderm of the chick during the second day of incubation. *Contributions to Embryology* **9,** 213-262.

Sanchez, M.-J., Holmes, A., Miles, C. and Dzierzak, E. (1996). Characterization of the first definitive hematopoietic stem cells in the AGM and liver of the mouse embryo. *Immunity* **5,** 513-525.

Sasaki, K., Yagi, H., Bronson, R. T., Tominaga, K., Matsunashi, T., Deguchi, K., Tani, Y., Kishimoto, T. and Komori, T. (1996). Absence of

fetal liver hematopoiesis in transcriptional co-activator, core binding factor β (*Cbfb*) deficient mice. *Proc. Natl. Acad. Sci. USA* **93,** 12359-12363.

Satake, M., Nomura, S., Yamaguchi-Iwai, Y., Takahama, Y., Hashimoto, Y., Niki, M., Yukihiko, K. and Ito, Y. (1995). Expression of the Runt domain encoding *PEBP2α* genes in T cells during thymic development. *Mol. Cell. Biol.* **15,** 1662-1670.

Sato, T. N., Tozawa, Y., Deutsch, U., Wolburg-Buchholz, K., Fujiwara, Y., Gendron-Maguire, M., Gridley, T., Wolburg, H., Risau, W. and Qin, Y. (1995). Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. *Nature* **376,** 70-74.

Shalaby, F., Ho, J., Stanford, W. L., Fischer, K.-D., Schuh, A., Schwartz, L., Bernstein, A. and Rossant, J. (1997). A requirement for *flk-1* in primitive and definitive hematopoiesis and vasculogenesis. *Cell* **89,** 981-990.

Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L. and Schuh, A. C. (1995). Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. *Nature* **376,** 62-66.

Shivdasani, R. A., Mayer, E. L. and Orkin, S. H. (1995). Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL. *Nature* **373,** 432-434.

Simeone, A., Daga, A. and Calabi, F. (1995). Expression of *runt* in the mouse embryo. *Dev. Dyn.* **203,** 61-70.

Stainier, D. Y. R., Weinstein, B. M., Detrich III, H. W., Zon, L. I. and Fishman, M. C. (1995). *cloche*, an early acting zebrafish gene, is required by both the endothelial and hematopoietic lineages. *Development* **121,** 3141-3150.

Takakura, N., Huang, S.-L., Naruse, T., Hamaguchi, I., Dumont, D. J., Yancopoulos, G. D. and Suda, T. (1998). Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis. *Immunity* **9,** 677-686.

Tavian, M., Coulombel, L., Luton, D., San Clemente, H., Dieterlen-Lièvre, F. and Peault, B. (1996). Aorta-associated CD34+ hematopoietic cells in the early human embryo. *Blood* **87,** 67-72.

Toles, J. F., Chui, D. H., Belbeck, L. W., Starr, E. and Barker, J. E. (1989). Hematopoietic stem cells in murine embryonic yolk sac and peripheral blood. *Proc. Natl. Acad. Sci. USA* **86,** 7456-7459.

Visvader, J. E., Fujiwara, Y. and Orkin, S. H. (1998). Unsuspected role for the T-cell leukemia protein SCL/tal-1 in vascular development. *Genes Dev.* **12,** 473-479.

Wang, Q., Stacy, T., Binder, M., Marín-Padilla, M., Sharpe, A. H. and Speck, N. A. (1996a). Disruption of the *Cbfa2* gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. *Proc. Natl. Acad. Sci. USA* **93,** 3444-3449.

Wang, Q., Stacy, T., Miller, J. D., Lewis, A. F., Huang, X., Bories, J.-C., Bushweller, J. H., Alt, F. W., Binder, M., Marín-Padilla, M., Sharpe, A. and Speck, N. A. (1996b). The CBFβ subunit is essential for CBFα2 (AML1) function in vivo. *Cell* **87,** 697-708.

Wang, S., Wang, Q., Crute, B. E., Melnikova, I. N., Keller, S. R. and Speck, N. A. (1993). Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. *Mol. Cell. Biol.* **13,** 3324-3339.

Watt, S. M., Williamson, J., Genevier, H., Fawcett, J., Simmons, D. L., Hatzfeld, A., Nesbitt, S. A. and Coombe, D. R. (1993). The heparin binding PECAM-1 adhesion molecule is expressed by CD34+ hematopoietic precursor cells with early myeloid and B-lymphoid cell phenotypes. *Blood* **82,** 2649-2663.

Weis, J., Fine, S. M., Chella, D., Savarirayan, S. and Sanes, J. R. (1991). Integration site-dependent expression of a transgene reveals specialized features of cells associated with neuromuscular junctions. *J. Cell Biol.* **113,** 1385-1397.

Weissman, I. L., Baird, S., Gartner, R. L., Papaioannou, V. E. and Raschke, W. (1977). Normal and neoplastic maturation of T-lineage lymphocytes. *Cold Spring Harbor Symp. Quant. Biol.* **41,** 9-21.

Wood, H. B., May, G., Healy, L., Enver, T. and Morriss-Kay, G. M. (1997). CD34 expression patterns during early mouse development are related to modes of blood vessel formation and reveal additional sites of hematopoiesis. *Blood* **90,** 2300-2311.

Yoder, M. C., Hiatt, K., Dutt, P., Mukherjee, P., Bodine, D. M. and Orlic, D. (1997). Characterization of definitive lymphohematopoietic stem cells in the day 9 murine yolk sac. *Immunity* **7,** 335-344.

Young, P. E., Baumhueter, S. and Lasky, L. A. (1995). The sialomucin CD34 is expressed on hematopoietic cells and blood vessels during murine development. *Blood* **85,** 96-105.